Thiakis Limited

Thiakis Limited is developing novel medicines for the treatment of obesity and metabolic disease. Thiakis is the exclusive licensee from Imperial Innovations of intellectual property relating to use of the gut hormones oxyntomodulin and PYY3-36 for the treatment of obesity and associated conditions, based on original research conducted by Professor Steve Bloom and colleagues at Imperial College London.

Visit Thiakis